Avanos Medical (AVNS) concentration risks

Avanos Medical's concentration profile centers on manufacturing geography rather than customer mix. The majority of manufacturing output is concentrated at two facilities the company operates in Mexico, a structural exposure that ties production continuity to a single country's operating conditions, logistics, and regulatory environment. That geographic concentration is compounded by a sourcing dependency: for quality assurance or cost effectiveness, the company purchases certain components and raw materials from sole suppliers, meaning a disruption at any one supplier could interrupt production regardless of the Mexico facilities' own performance. By contrast, customer concentration is comparatively contained — sales to Medline Industries accounted for approximately 12% of consolidated net sales in the most recent year, a share that sits at the low end of the disclosed bands. Netting these out, the two structural and dependency exposures around manufacturing footprint and sole-sourced inputs are the more consequential ones for the long-term verdict, since they touch the company's ability to produce and ship at all, while the Medline relationship, though a real customer dependency, represents a comparatively smaller share of revenue that would be easier to absorb if it changed.

For the engine’s reasoning on AVNS’s current verdict — including which dimensions drove the score — see the per-dimension breakdown.

Concentration counts reflect items disclosed in each peer’s most recent 10-K; disclosed-size classification uses TrendMatrix’s internal 10-K extraction taxonomy.